Company profile: Bryn Pharma
1.1 - Company Overview
Company description
- Provider of nasal-based epinephrine for anaphylaxis, including NDS1C, a needle-free, easy-to-use epinephrine nasal spray for the treatment of anaphylaxis. Also offers a Clinical Development Program focused on demonstrating the pharmacokinetic parameters and safety of NDS1C compared to the 0.3 mg IM epinephrine autoinjector.
Products and services
- Clinical Development Program: A comparative program demonstrating pharmacokinetic parameters and safety of NDS1C versus the 0.3 mg IM epinephrine autoinjector
- Nasal-Based Epinephrine: The company offers epinephrine via nasal delivery for anaphylaxis, utilizing nasal-based design approach
- NDS1C: A needle-free, easy-to-use epinephrine nasal spray developed for the treatment of anaphylaxis via intranasal administration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bryn Pharma
Aera Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary protein nanoparticle (PNP) delivery platform based on human proteins to deliver genetic medicines across modalities and therapeutic areas, and a therapeutic enzyme platform with novel, compact, programmable gene-editing enzymes to overcome packaging and delivery challenges in gene therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aera Therapeutics company profile →
BioAtla
HQ: United States
Website
- Description: Provider of conditionally active biologics (CABs) for cancer-targeted therapeutics activated under specific physiological conditions; the CIAO! platform for antibody optimization; CAB-ADCs, CAB-CAR-T, and CAB-Bispecifics to improve safety and efficacy; and Mecbotamab Vedotin, a CAB-AXL-ADC for AXL-expressing tumors evaluated in sarcoma and NSCLC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioAtla company profile →
Hycor Biomedical
HQ: United States
Website
- Description: Provider of diagnostic systems and assays for allergy and mast cell activation, including NOVEOS for allergy testing with small sample volumes; NOVEOS assay reagents, consumables, and supplies for specific IgE tests; a Tryptase Assay chemiluminescent microparticle immunoassay for serum tryptase detection; and TASSO+, a capillary blood collection device compatible with NOVEOS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hycor Biomedical company profile →
Phenex Pharmaceuticals
HQ: Germany
Website
- Description: Provider of drug discovery and development focused on novel pharmaceuticals, leveraging small-molecule expertise. Privately held, founded in 2002, with Biology and Chemistry laboratories and offices in the Biotech Cluster Rhine-Neckar, primarily in Heidelberg and partly in Ludwigshafen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phenex Pharmaceuticals company profile →
Sudo Biosciences
HQ: United States
Website
- Description: Provider of TYK2 pseudokinase domain–targeting medicines, including a brain-penetrant TYK2 inhibitor for multiple sclerosis and neurodegenerative diseases, and a topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sudo Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bryn Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bryn Pharma
2.2 - Growth funds investing in similar companies to Bryn Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bryn Pharma
4.2 - Public trading comparable groups for Bryn Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →